ENANTA PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
ENTA$11.22-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended June 30, | Nine Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | ||||
| Royalty revenue | $14,359 | $18,314 | $50,133 | $50,199 |
| Total revenue | 14,359 | 18,314 | 50,133 | 50,199 |
| Operating expenses: | ||||
| Research and development | 22,126 | 27,210 | 62,428 | 82,931 |
| General and administrative | 9,469 | 9,997 | 28,046 | 34,231 |
| Total operating expenses | 31,595 | 37,207 | 90,474 | 117,162 |
| Loss from operations | (17,236) | (18,893) | (40,341) | (66,963) |
| Other income (expense): | ||||
| Interest expense | (4,130) | (1,618) | (10,529) | (5,294) |
| Interest and investment income, net | 1,901 | 2,285 | 6,407 | 7,376 |
| Total other (expense) income, net | (2,229) | 667 | (4,122) | 2,082 |
| Loss before income taxes | (19,465) | (18,226) | (44,463) | (64,881) |
| Income tax (expense) benefit | (36) | (29) | (67) | 1,692 |
| Net loss | $(19,501) | $(18,255) | $(44,530) | $(63,189) |
| Net loss per share, basic and diluted | $(0.67) | $(0.85) | $(1.54) | $(2.96) |
| Weighted average common shares outstanding, basic and diluted | 29,090 | 21,377 | 28,958 | 21,322 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.